Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's DiseaseGlobeNewsWire • 03/20/24
Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's DiseaseGlobeNewsWire • 02/14/24
Annovis: Potentially Encouraging Anecdotes, Weighing Phase 3 Parkinson's ProspectsSeeking Alpha • 02/12/24
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's PortfolioGlobeNewsWire • 01/30/24
Annovis Bio Refines Timeline for Parkinson's Phase III Study Data AnnouncementGlobeNewsWire • 01/24/24
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson's DiseaseGlobeNewsWire • 12/05/23
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer's Disease Trial, Exceeding Original ProjectionsGlobeNewsWire • 11/27/23
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/08/23
Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer's Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)Business Wire • 10/30/23
Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease ConferenceBusiness Wire • 10/24/23
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer's StudyGlobeNewsWire • 10/12/23
Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateBusiness Wire • 08/15/23